63.94
-1.14 (-1.75%)
| Previous Close | 65.08 |
| Volume | 4,455,888 |
| Price / Earnings (Forward) | 9.83 |
| Price / Sales | 3.75 |
| Price / Book | 1.99 |
| 52 Weeks Range |
| Profit Margin | 17.76% |
| Operating Margin (TTM) | 30.05% |
| Diluted EPS (TTM) | 2.70 |
| Quarterly Revenue Growth (YOY) | 14.80% |
| Quarterly Earnings Growth (YOY) | 109.40% |
| Total Debt/Equity (MRQ) | 10.39% |
| Current Ratio (MRQ) | 5.52 |
| Operating Cash Flow (TTM) | 700.26 M |
| Levered Free Cash Flow (TTM) | 411.56 M |
| Return on Assets (TTM) | 6.38% |
| Return on Equity (TTM) | 9.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | BioMarin Pharmaceutical Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 3.0 |
| Price Volatility | -3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.55 |
|
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.77% |
| % Held by Institutions | 98.91% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PLENGE ROBERT M | 65.51 | - | 6,140 | 402,231 |
| Aggregate Net Quantity | 6,140 | |||
| Aggregate Net Value ($) | 402,231 | |||
| Aggregate Avg. Buy ($) | 65.51 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PLENGE ROBERT M | Director | 10 Sep 2026 | Acquired (+) | 6,140 | 65.51 | 402,231 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |